
NeoGenomics NEO
$ 12.4
0.16%
Quarterly report 2025-Q2
added 07-29-2025
NeoGenomics EV/EBITDA Ratio 2011-2026 | NEO
Annual EV/EBITDA Ratio NeoGenomics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -33.5 | 269 | 75.3 | 47.5 | 26.9 | 24.3 | 299 | 23.1 | 27.8 | 26.7 | 45.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 299 | -33.5 | 75.6 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
-2.25 | $ 3.1 | 2.31 % | $ 101 K | ||
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Brainsway Ltd.
BWAY
|
-43.6 | $ 24.05 | -2.67 % | $ 99.4 M | ||
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
-21.2 | $ 39.16 | -0.89 % | $ 1.09 B | ||
|
Burning Rock Biotech Limited
BNR
|
-1.51 | $ 33.54 | -5.15 % | $ 361 M | ||
|
Danaher Corporation
DHR
|
20.1 | $ 219.62 | -2.19 % | $ 161 B | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | $ 102.3 | 0.05 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
2.58 | $ 26.24 | -0.61 % | $ 793 M | ||
|
BioNano Genomics
BNGO
|
-7.71 | $ 1.47 | -2.65 % | $ 1.87 M | ||
|
Guardant Health
GH
|
-28.8 | $ 110.48 | 0.68 % | $ 13.6 B | ||
|
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
3.62 | - | - | $ 79.8 M | ||
|
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 66.68 | 0.56 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
39.5 | $ 74.0 | 0.87 % | $ 28.6 B | ||
|
CareDx, Inc
CDNA
|
-100 | $ 20.8 | 1.66 % | $ 1.12 B | ||
|
Celcuity
CELC
|
-2.38 | $ 112.12 | -2.1 % | $ 4.42 B | ||
|
DarioHealth Corp.
DRIO
|
-1.05 | $ 10.3 | -6.02 % | $ 292 M | ||
|
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | ||
|
Precipio
PRPO
|
-1.8 | $ 24.26 | -1.98 % | $ 31.5 M | ||
|
Personalis
PSNL
|
-7.07 | $ 9.97 | -0.2 % | $ 591 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-1.42 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
70.5 | $ 149.69 | -0.11 % | $ 23.8 B | ||
|
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
24.1 | $ 235.62 | -1.73 % | $ 42.7 B | ||
|
Thermo Fisher Scientific
TMO
|
19.3 | $ 592.16 | -2.61 % | $ 226 B | ||
|
Trinity Biotech plc
TRIB
|
12.6 | $ 0.87 | -4.13 % | $ 61.9 M | ||
|
Charles River Laboratories International
CRL
|
22 | $ 211.68 | -2.4 % | $ 10.9 B | ||
|
Twist Bioscience Corporation
TWST
|
-23.6 | $ 41.58 | -1.02 % | $ 2.49 B | ||
|
Medpace Holdings
MEDP
|
30.7 | $ 593.07 | -0.81 % | $ 18.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 182.35 | -0.21 % | $ 20.2 B | ||
|
Biodesix
BDSX
|
-4.25 | $ 9.66 | -6.49 % | $ 1.25 B | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 269.81 | 0.66 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
827 | $ 1 392.8 | -0.63 % | $ 29.6 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 185.89 | -0.23 % | $ 15.3 B | ||
|
IDEXX Laboratories
IDXX
|
45.3 | $ 676.71 | -1.6 % | $ 55.8 B |